Goldman Sachs raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $8 from $7 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics Announces $75M Share Offering
- MoonLake Immunotherapeutics’ SLK Program: Buy Rating Backed by Promising Trial Results and Upcoming Catalysts
- MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating
- MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab
- MoonLake prices 7.14M shares at $10.50 in underwritten offering